The marketing division will use digital media platform and other means to help market and sell new products in the industry. Matching the right product with the right marketing tools and strategy to increase the effectiveness of the marketing activity.
Case Study
Circulating Tumour DNA (ctDNA) Liquid Biopsy
Our marketing strategy highlights the game-changing potential of real-time, non-invasive monitoring in managing metastatic cancer. By providing critical insights without the discomfort of invasive procedures, we empower individuals throughout their cancer journey.
Imagine Tracking Metastatic Cancer With Precision, Without the Need for Invasive Methods!
The collaboration between CHEQ Technologies and partners like AGTC Genomics forms a powerful alliance focused on driving innovation and mutual success. By pooling our resources, we aim to elevate our marketing strategies and create synergies for highly efficient, impactful outcomes. This partnership goes beyond marketing, it’s about developing and promoting unique, proprietary products that distinguish our collaboration. Our work with AGTC Genomics in the field of genomics testing showcases our shared vision, as we leverage our combined expertise to launch groundbreaking products and effectively reach the right audience.
LiquidDx™: A Revolutionary Non-Invasive Cancer Test
The LiquidDx™ circulating tumor DNA (ctDNA) liquid biopsy tests for cancer cells in your blood, rather than a tissue sample from your body. This test looks for microscopic fragments of DNA from cancer cells in your circulation using cutting-edge technology known as next-generation sequencing. This type of testing is more precise and specific than typical cancer tests, and it can reveal critical information about the changes in your cancer cells. The best aspect is that ctDNA liquid biopsy is non-invasive, which means no tissue samples are collected from your body, making it a more convenient and painless way to monitor cancer.
Circulating Tumor DNA: A Non-Invasive Alternative to Traditional Biopsies
Tumors release DNA into the bloodstream, known as circulating tumor DNA (ctDNA). This ctDNA provides critical insights into the genetic makeup of a patient’s tumor, offering a powerful, non-invasive alternative to traditional tissue biopsies for cancer diagnosis and ongoing monitoring. By simply analyzing a blood sample, ctDNA can reveal key genetic mutations within the tumor, helping to guide treatment choices and track therapy effectiveness. LiquidDx™ goes further by assessing multiple tissues and biomarkers from plasma samples, offering comprehensive genomic profiling that consolidates hundreds of genetic markers into a single, efficient assay.
DNA from tumors circulates in the blood
Cell-free DNA is extracted from plasma
Comprehensive genomic profiling can detect multiple variant types in circulating tumor DNA